We have established a system for respiratory therapy medications that meets legal requirements, insures accuracy, and assures that the medications are effective, compatible, and sterile. Its institution in our hospital procedure was preceded by detailed studies and by careful considerations of the advantages and disadvantages. The slight increase in the patient charge appears to be more than justified by the improved patient care and the decreased probability of liability.
Get full access to this article
View all access options for this article.
References
1.
SimkinsT: Drugs a grey area in inhalation therapy. Resp Ther1:23, 1971.
2.
PettyTL: Why not take inhalation therapy seriously?Chest57:403, 1970.
3.
BoydS: Unit dose: a possible answer to contamination risk in IPPB nebulizer solutions. Resp Care18:428, 1973.
